Online inquiry

IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2387MR)

This product GTTS-WQ2387MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_000733.4; NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 4072
UniProt ID P07766; P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2387MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12240MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ1798MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ1364MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ4752MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ8001MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ7240MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ4121MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ2687MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 785
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW